Literature DB >> 15270842

Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice.

Y Kannan1, M Tokunaga, M Moriyama, H Kinoshita, Y Nakamura.   

Abstract

Patients with poorly controlled diabetes are at high risk of acquiring bacterial infections. However, conflicting results have been reported on neutrophil function in diabetes. We periodically evaluated neutrophil dysfunction in multiple low-dose streptozotocin (STZ)-induced diabetic mice, and then evaluated the effects of troglitazone and other thiazolidinediones (TZDs) on the decline of neutrophil function. Zymosan was injected intraperitoneally and neutrophil infiltration and phagocytosis were evaluated. While phagocytosis of zymosan by peritoneal neutrophils was consistently reduced in diabetic mice, neutrophil infiltration was decreased on day 30, but increased on day 40 after STZ injection. The in vitro chemotactic and phagocytic activities of blood neutrophils in mice that did not receive zymosan were consistently reduced in diabetic mice. Phorbol myristate acetate (PMA)-stimulated superoxide production by zymosan-induced peritoneal neutrophils and the levels of zymosan-induced tumour necrosis factor (TNF)-alpha and interleukin (IL)-1beta in peritoneal exudate fluids were also reduced in the diabetic mice. Treatment of the diabetic mice with troglitazone beginning 2 weeks after STZ injection did not improve hyperglycaemia but did prevent the decline of zymosan-induced neutrophil infiltration on day 30, and additionally promoted the increased infiltration on day 40. Troglitazone also promoted the chemotactic activity of blood neutrophils isolated from normal mice in vitro. Rosiglitazone but not pioglitazone induced a similar effect. Neutrophil phagocytosis was not enhanced by troglitazone either in vivo or in vitro. Taken together, neutrophil function is impaired by STZ-induced diabetes, but inflammatory infiltration does not always vary with the chemotactic disability or cytokine levels. Furthermore, troglitazone and rosiglitazone were suggested to improve at least neutrophil chemotactic activity in these animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270842      PMCID: PMC1809107          DOI: 10.1111/j.1365-2249.2004.02532.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

Review 1.  Troglitazone and related compounds: therapeutic potential beyond diabetes.

Authors:  T Fujiwara; H Horikoshi
Journal:  Life Sci       Date:  2000-10-06       Impact factor: 5.037

2.  Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

Authors:  J Sakamoto; H Kimura; S Moriyama; H Odaka; Y Momose; Y Sugiyama; H Sawada
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

3.  Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects.

Authors:  A Aljada; H Ghanim; J Friedman; R Garg; P Mohanty; P Dandona
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

4.  Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium.

Authors:  N G Chen; X Han
Journal:  Biochem Biophys Res Commun       Date:  2001-04-06       Impact factor: 3.575

5.  Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes.

Authors:  M A Mazade; M S Edwards
Journal:  Mol Genet Metab       Date:  2001-07       Impact factor: 4.797

6.  Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia.

Authors:  J Y Hokama; L S Ritter; G Davis-Gorman; A D Cimetta; J G Copeland; P F McDonagh
Journal:  J Diabetes Complications       Date:  2000 Mar-Apr       Impact factor: 2.852

7.  Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects.

Authors:  R Garg; Y Kumbkarni; A Aljada; P Mohanty; H Ghanim; W Hamouda; P Dandona
Journal:  Hypertension       Date:  2000-09       Impact factor: 10.190

8.  Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo.

Authors:  I Utsunomiya; M Ito; S Oh-ishi
Journal:  Cytokine       Date:  1998-12       Impact factor: 3.861

Review 9.  Glitazones: clinical effects and molecular mechanisms.

Authors:  Michael Stumvoll; Hans-Ulrich Häring
Journal:  Ann Med       Date:  2002       Impact factor: 4.709

Review 10.  Phagocytosis--the mighty weapon of the silent warriors.

Authors:  Meir Djaldetti; Hertzel Salman; Michael Bergman; Ruth Djaldetti; Hanna Bessler
Journal:  Microsc Res Tech       Date:  2002-06-15       Impact factor: 2.769

View more
  4 in total

1.  Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model.

Authors:  M Jiménez-González; F Jaques; S Rodríguez; A Porciuncula; R M Principe; G Abizanda; M Iñiguez; J Escalada; J Salvador; F Prósper; P A Halban; M Barajas
Journal:  Diabetologia       Date:  2013-01-29       Impact factor: 10.122

2.  The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.

Authors:  Ming Zhang; Xiao-Yan Lv; Jing Li; Zhi-Gang Xu; Li Chen
Journal:  Exp Diabetes Res       Date:  2009-01-04

Review 3.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

4.  Hyperglycemia Impairs Neutrophil-Mediated Bacterial Clearance in Mice Infected with the Lyme Disease Pathogen.

Authors:  Ashkan Javid; Nataliya Zlotnikov; Helena Pětrošová; Tian Tian Tang; Yang Zhang; Anil K Bansal; Rhodaba Ebady; Maitry Parikh; Mijhgan Ahmed; Chunxiang Sun; Susan Newbigging; Yae Ram Kim; Marianna Santana Sosa; Michael Glogauer; Tara J Moriarty
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.